Shanghai Henlius Biotech Co. Ltd. has announced the successful completion of a Phase I/II clinical trial to assess the safety and preliminary efficacy of HLX04-O (bevacizumab), a recombinant anti-VEGF humanized monoclonal antibody injection jointly developed with Essex Bio-Technology Limited. HLX04-O has the potential to be one of the first bevacizumab products approved for ophthalmic diseases, an indication where it is currently used off-label.
Henlius Announces Positive Phase I/II Results For Ophthalmic Bevacizumab Biosimilar
HLX04-O Could Be One Of The First Bevacizumab Products Formally Indicated For Ophthalmology
Henlius has successfully established the safety and preliminary efficacy of its ophthalmology-indicated bevacizumab biosimilar HLX04-O in Phase I/II trials.
More from Products
More from Generics Bulletin
• By
Off-patent drug trade groups expressed their concerns that personnel and expertise cuts will affect the agency’s ability to review and approve generics and biosimilars.
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
FDA staffing cuts are making negotiation preparations more difficult, but also could mean the result is a smaller user fee renewal package.